First Tracks Biotherapeutics (HAM:B43) Revenue: € Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €37.60
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Revenue?

First Tracks Biotherapeutics HAM:B43 -2.84% 20 Revenue is € Mil as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

First Tracks Biotherapeutics's revenue for the six months ended in Dec. 2024 was €0.00 Mil. First Tracks Biotherapeutics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2024. First Tracks Biotherapeutics's Revenue per Share for the six months ended in Dec. 2024 was €0.00. First Tracks Biotherapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

First Tracks Biotherapeutics  (HAM:B43) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

First Tracks Biotherapeutics Revenue Related Terms

First Tracks Biotherapeutics Revenue Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Revenue Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Revenue
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Revenue 0.00 0.00

HAM:B43 vs AVLN, IMTX, ARDX: Revenue Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's Revenue falls into.


HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of € Mil mean?
First Tracks Biotherapeutics (HAM:B43) has a Revenue of € Mil as of Dec. 2024. Revenue is the total amount a company generates as sales through its operations. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Revenue too high?
First Tracks Biotherapeutics' current Revenue is € Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Revenue compare to AVLN and IMTX?
First Tracks Biotherapeutics' Revenue of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Revenue is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Revenue of € Mil. The current Revenue is € Mil. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Revenue is € Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.60
Price